This drug is an approved fixed-dose combination of the drugs hydrochlorothiazide and candesartan, available in 32 mg, 25 mg, and 16 mg, 12.5 mg, which comprises candesartan cilexetil USP equivalent to 32 mg and hydrochlorothiazide USP equivalent to 25 mg of hydrochlorothiazide. Other ingredients are also present.


Usage of this drug is indicated in the treatment of moderate to severe hypertension, used for decreasing the overall workload on the heart and other blood vessels, in the prevention of strokes, the prevention of heart attacks, and the treatment of kidney problems.

Side effects

A mild to moderate range of side effects has been observed. Side effects such as dizziness, fatigue, nausea, headache, vomiting, dry mouth, increased heart rate, itching, and rash in some cases, blurred vision, no urination, pruritus, urticaria, Hyperkalemia, hyponatremia, and angioedema in some cases.


This medication is to be prescribed cautiously in patients with hepatic disorders or renal impairment. In case of pregnancy not to be prescribed, not to use this fixed dose combination drug along with any other drug containing Aliskiren.


This medication is contraindicated in patients with diabetes or diabetes type 2, in patients with a previous history of hypersensitivity to hydrochlorothiazide, hypersensitivity to candesartan, or any other of the constituents, and in patients with hypercholesterolemia.

Dosage and administration

In adults with hypertension, the usual dosage consists of candesartan 16 to 32 mg and hydrochlorothiazide 12.5 to 50 mg, to be administered orally in daily divided doses accordingly.


We have also established roots and begun this new venture in other countries as well, such as Kazakhstan, China, Ecuador, Spain, Yemen, Israel, and Oman.

Available Forms